Disclosure Of First-Time Adoption [Text Block]

Innate Pharma - Filing #2813423

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	54 151 EUR	—	—	—	—	58 103 EUR	—	819,000 EUR	—	—	379 637 EUR	272 213 EUR	4 011 EUR	—	219 404 EUR	—	— EUR	—	456,000 EUR	—	— EUR	1 054 EUR	107 440 EUR	1 054 EUR	—	52 809 EUR	—	— EUR	— EUR	— EUR	— EUR	375 220 EUR	—	3 978 EUR	—	—	156 476 EUR	63 984 EUR	3 950 EUR	355,000 EUR	372 131 EUR	155 976 EUR
Comprehensive income	—	— EUR	362,000 EUR	57 741 EUR	— EUR	—	58 103 EUR	—	— EUR	— EUR	—	—	—	— EUR	—	— EUR	—	52 809 EUR	—	101,000 EUR	—	—	—	—	— EUR	—	— EUR	—	—	—	—	—	— EUR	—	52 708 EUR	— EUR	—	—	—	—	—	—
Profit (loss)	—	— EUR	— EUR	58 103 EUR	— EUR	—	58 103 EUR	—	— EUR	— EUR	—	—	—	— EUR	—	— EUR	—	52 809 EUR	—	— EUR	—	—	—	—	— EUR	—	— EUR	—	—	—	—	—	— EUR	—	52 809 EUR	— EUR	—	—	—	—	—	—